sorafenib has been researched along with 2-piperidone in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (2-piperidone) | Trials (2-piperidone) | Recent Studies (post-2010) (2-piperidone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,305 | 65 | 594 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T | 1 |
1 other study(ies) available for sorafenib and 2-piperidone
| Article | Year |
|---|---|
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2013 |